Acarix AB ACIXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.03
- Day Range
- $0.02–0.02
- 52-Week Range
- $0.02–0.04
- Bid/Ask
- $0.00 / $9,200.07
- Shares Outstanding
- 1.24B
- Market Cap
- $19.80M
- Volume/Avg
- 20,000 / 170,177
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.04
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 8
- Website
- https://www.acarix.com
Valuation
|
Metric
|
ACIXF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.68 |
Price/Sales | 20.04 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ACIXF
|
|---|---|
Quick Ratio | 9.12 |
Current Ratio | 10.67 |
Interest Coverage | −21.60 |
Quick Ratio
ACIXF
Profitability
|
Metric
|
ACIXF
|
|---|---|
Return on Assets (Normalized) | −83.95% |
Return on Equity (Normalized) | −96.00% |
Return on Invested Capital (Normalized) | −92.84% |
Return on Assets
ACIXF
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|L$lX#^ | LOCK|k>L# | $179B | |||
| Medtronic PLC
MDT
| LOCK|t!Y^#& | LOCK|h?DN | $122B | |||
| Stryker Corp
SYK
| LOCK|Cd@M>@q% | LOCK|#s? | $118B | |||
| Boston Scientific Corp
BSX
| LOCK|<T^Hx<j | LOCK|gz>x | $66B | |||
| Edwards Lifesciences Corp
EW
| LOCK|&ktpfR>b | LOCK|Pl?L | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|&P!sP< | LOCK|#j | $32B | |||
| DexCom Inc
DXCM
| LOCK|#^zN$ny^ | LOCK|kK^z | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|G^ | LOCK|VP | $26B | |||
| Steris PLC
STE
| LOCK|!pCT%N | LOCK|v%xF | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|x&L^c#>< | LOCK|cWh | $19B |
United States